共 330 条
[1]
Jonker DJ(2007)Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040-8
[2]
O’Callaghan CJ(2011)Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011-9
[3]
Karapetis CS(2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663-71
[4]
Zalcberg JR(2011)Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastaticcolorectal cancer: the OPUS study Ann Oncol 22 1535-46
[5]
Tu D(2012)Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 1466-75
[6]
Au HJ(2011)Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2103-14
[7]
Berry SR(2009)Toxicity associated with combination oxaliplatin plus fluoropyrimidinewith or without cetuximab in the MRC COIN trial experience Br J Cancer 100 251-8
[8]
Krahn M(2003)Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 1307-12
[9]
Price T(2009)Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer. 2009 ASCO Annual Meeting J Clin Oncol 27 e15053-45
[10]
Simes RJ(2010)Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study Ann Oncol 21 1537-8